<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01922336</url>
  </required_header>
  <id_info>
    <org_study_id>SB2-G11-NHV</org_study_id>
    <secondary_id>2012-005306-22</secondary_id>
    <nct_id>NCT01922336</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB2 in Healthy Subjects</brief_title>
  <official_title>A Randomised, Single-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Three Formulations of Infliximab (SB2, EU Sourced Remicade® and US Sourced Remicade®) in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Bioepis Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Bioepis Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the pharmacokinetics, safety, tolerability and
      immunogenicity of SB2 and Remicade (EU sourced Remicade and US sourced Remicade) in healthy
      subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time zero to infinity (AUCinf)</measure>
    <time_frame>71 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum serum concentration (Cmax)</measure>
    <time_frame>71 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time zero to the last quantifiable concentration (AUClast)</measure>
    <time_frame>71 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (Tmax)</measure>
    <time_frame>71 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">159</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>SB2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SB2 (Study drug)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EU Remicade</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EU sourced Remicade (Reference drug)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>US Remicade</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>US sourced Remicade (Reference drug)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SB2</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>SB2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EU Remicade</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>EU Remicade</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>US Remicade</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>US Remicade</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy female subjects of non-childbearing potential and healthy male subjects

          -  Have a body weight between 60.0 and 94.9 kg and a body mass index between 20.0 and
             29.9 kg/m², inclusive.

        Exclusion Criteria:

          -  history and/or current presence of clinical significant atopic allergy,
             hypersensitivity or allergic reactions, also including known or suspected clinically
             relevant drug hypersensitivity to any components of the test and reference IP
             formulation or comparable drugs.

          -  active or latent Tuberculosis or who have a history of Tuberculosis.

          -  history of invasive systemic fungal infections or other opportunistic infections

          -  systemic or local infection, a known risk for developing sepsis and/or known active
             inflammatory process

          -  serious infection associated with hospitalisation and/or which required intravenous
             antibiotics

          -  history of and/or current cardiac disease

          -  have received live vaccine(s) within 30 days prior to Screening or who will require
             live vaccine(s) between Screening and the final study visit.

          -  Intake medication with a half-life &gt; 24 h within 1 month or 10 half-lives of the
             medication prior to the administration of investigational product.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rainard Fuhr, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parexel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parexel International GmbH</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2013</study_first_submitted>
  <study_first_submitted_qc>August 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2013</study_first_posted>
  <last_update_submitted>July 10, 2017</last_update_submitted>
  <last_update_submitted_qc>July 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

